ZEISS and Boehringer Ingelheim aim to change course of retinal diseases

ZEISS’s Euan S. Thomson, Ph.D., President of Ophthalmology & Head of Digital Business, and Ulrike Graefe-Mody, Ph.D., Head of Retinal Health at Boehringer Ingelheim, dig into the details of a new collaboration, discussing data-driven artificial intelligence in the pursuit of earlier detection and prediction capabilities.
*The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support. Not all products/services are available in all countries.